NeuroPace, Inc. (NASDAQ:NPCE), a medical device company specializing in neurological disorders with a market capitalization of $439 million, has been making significant strides in the epilepsy ...

Responsive neurostimulation has also shown promising results, particularly in patients with idiopathic generalized epilepsy (IGE). A case series reported significant reductions in seizure ...

NeuroPace provided initial financial guidance targets for 2025: Revenue of $92 million – $96 million, representing growth of 15.5% – 20.5% versus the midpoint of the expected 2024 revenue range of $79 ...

20%+ revenue CAGR Indication expansion to include Idiopathic Generalized and Pediatric drug-resistant epilepsy patients Become the neuromodulation category leader in efficiency and ease of use ...